Contrasting Rockwell Medical (RMTI) and Repligen Corporation (RGEN)
Repligen Corporation (NASDAQ: RGEN) and Rockwell Medical (NASDAQ:RMTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.
Earnings and Valuation
This table compares Repligen Corporation and Rockwell Medical’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Repligen Corporation||$113.32 million||12.69||$29.54 million||$0.51||75.49|
|Rockwell Medical||$54.04 million||6.77||-$21.07 million||($0.42)||-16.83|
Repligen Corporation has higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Repligen Corporation, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
97.9% of Repligen Corporation shares are owned by institutional investors. Comparatively, 21.4% of Rockwell Medical shares are owned by institutional investors. 1.5% of Repligen Corporation shares are owned by insiders. Comparatively, 15.9% of Rockwell Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Repligen Corporation has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 2.17, indicating that its stock price is 117% more volatile than the S&P 500.
This is a summary of recent ratings and price targets for Repligen Corporation and Rockwell Medical, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Repligen Corporation presently has a consensus price target of $46.00, indicating a potential upside of 19.48%. Rockwell Medical has a consensus price target of $9.33, indicating a potential upside of 32.01%. Given Rockwell Medical’s higher possible upside, analysts clearly believe Rockwell Medical is more favorable than Repligen Corporation.
This table compares Repligen Corporation and Rockwell Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Repligen Corporation beats Rockwell Medical on 10 of the 14 factors compared between the two stocks.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.
About Rockwell Medical
Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company’s drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Calcitriol (active vitamin D) injection is indicated for treatment of secondary hyperparathyroidism in dialysis patients.
Receive News & Stock Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related stocks with our FREE daily email newsletter.